◼ Archived
Business
🔮 fades
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
Eli Lilly's $3.8 billion acquisition of AtaiBeckley signals a major shift as Big Pharma begins to validate the psychedelic medicine sector.